| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -63,837 | -25,143 | -49,507 | -125,672 |
| Goodwill impairment | 0 | 0 | 12,625 | 59,138 |
| Amortization of intangible assets | 89,826 | 92,039 | 85,757 | 172,968 |
| Stock-based compensation | 14,611 | 15,911 | 16,996 | 47,507 |
| Depreciation of property and equipment | 2,461 | 2,800 | 2,612 | 7,902 |
| Amortization of right-of-use assets | 1,898 | 4,383 | 3,783 | 4,190 |
| Provision for allowances for doubtful accounts | -79 | 482 | -858 | 377 |
| Deferred income taxes | -1,060 | -9,958 | 2,623 | -34,072 |
| Other, net | -1,329 | -3,127 | -1,223 | -2,049 |
| Accounts receivable | 20,996 | -17,462 | -16,161 | 8,497 |
| Prepaid expenses and other current assets | 29,446 | -8,014 | -15,108 | 16,434 |
| Inventory | -6,315 | -1,438 | 1,900 | -861 |
| Other assets | -336 | -1,606 | 1,225 | -7,616 |
| Accounts payable | -2,108 | -4,802 | -3,022 | 19,278 |
| Accrued expenses and other current liabilities | 39,114 | -20,737 | 2,902 | -5,149 |
| Accrued compensation | -31,529 | 18,091 | 4,750 | -9,545 |
| Deferred revenue | 5,060 | -9,985 | -3,693 | -6,084 |
| Operating lease liabilities | -2,297 | -3,379 | -5,079 | -5,170 |
| Other liabilities | -82 | -3,607 | 8 | -3,912 |
| Net cash provided by operating activities | 9,516 | 87,742 | 99,264 | 107,351 |
| Proceeds from the sale of investment | NaN | 0 | 0 | 740 |
| Capital expenditures | 1,660 | 2,619 | 2,280 | 3,994 |
| Asset acquisition resulting in net intangible assets | NaN | 0 | 0 | 29,569 |
| Capitalized software development costs | 34,162 | 31,700 | 29,038 | 57,824 |
| Acquisitions accounted for as business combinations, net of cash acquired | 0 | 0 | 16,602 | 65,302 |
| Payments for investments | 700 | 0 | 800 | 27,075 |
| Other, net | NaN | 0 | 0 | -60 |
| Net cash used in investing activities | -36,522 | -34,319 | -48,720 | -182,964 |
| Proceeds from employee stock purchase plan | NaN | NaN | 517 | 1,384 |
| Repayment of convertible senior notes | NaN | 0 | 0 | 550,629 |
| Proceeds from the exercise of stock options | 0 | 4 | 0 | 81 |
| Payment of credit facility issuance costs | NaN | -1 | 4,109 | NaN |
| Proceeds from employee stock purchase plan | 399 | 3,000 | NaN | NaN |
| Other, net | -2,848 | 0 | 0 | 0 |
| Net cash (used in) provided by financing activities | -2,449 | 1,104 | -3,592 | -549,164 |
| Net decrease in cash and cash equivalents | -29,455 | 54,527 | 46,952 | -624,777 |
| Effect of foreign currency exchange rate changes | -891 | 308 | 5,747 | NaN |
| Cash and cash equivalents at beginning of the period | 781,084 | 726,249 | 1,298,327 | NaN |
| Cash and cash equivalents at end of the period | 750,738 | 781,084 | 726,249 | NaN |
Teladoc Health, Inc. (TDOC)
Teladoc Health, Inc. (TDOC)